» Articles » PMID: 26080908

MiRNA-embedded ShRNAs for Lineage-specific BCL11A Knockdown and Hemoglobin F Induction

Abstract

RNA interference (RNAi) technology using short hairpin RNAs (shRNAs) expressed via RNA polymerase (pol) III promoters has been widely exploited to modulate gene expression in a variety of mammalian cell types. For certain applications, such as lineage-specific knockdown, embedding targeting sequences into pol II-driven microRNA (miRNA) architecture is required. Here, using the potential therapeutic target BCL11A, we demonstrate that pol III-driven shRNAs lead to significantly increased knockdown but also increased cytotoxcity in comparison to pol II-driven miRNA adapted shRNAs (shRNA(miR)) in multiple hematopoietic cell lines. We show that the two expression systems yield mature guide strand sequences that differ by a 4 bp shift. This results in alternate seed sequences and consequently influences the efficacy of target gene knockdown. Incorporating a corresponding 4 bp shift into the guide strand of shRNA(miR)s resulted in improved knockdown efficiency of BCL11A. This was associated with a significant de-repression of the hemoglobin target of BCL11A, human γ-globin or the murine homolog Hbb-y. Our results suggest the requirement for optimization of shRNA sequences upon incorporation into a miRNA backbone. These findings have important implications in future design of shRNA(miR)s for RNAi-based therapy in hemoglobinopathies and other diseases requiring lineage-specific expression of gene silencing sequences.

Citing Articles

Transcriptional Repressor BCL11A in Erythroid Cells.

Zheng G, Orkin S Adv Exp Med Biol. 2024; 1459:199-215.

PMID: 39017845 DOI: 10.1007/978-3-031-62731-6_9.


Suppression of toxic transgene expression by optimized artificial miRNAs increases AAV vector yields in HEK-293 cells.

Blahetek G, Mayer C, Zuber J, Lenter M, Strobel B Mol Ther Methods Clin Dev. 2024; 32(3):101280.

PMID: 39015407 PMC: 11250862. DOI: 10.1016/j.omtm.2024.101280.


A novel high-titer, bifunctional lentiviral vector for autologous hematopoietic stem cell gene therapy of sickle cell disease.

Hart K, Liu B, Brown D, Campo-Fernandez B, Tam K, Orr K Mol Ther Methods Clin Dev. 2024; 32(2):101254.

PMID: 38745893 PMC: 11091523. DOI: 10.1016/j.omtm.2024.101254.


Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.

Rajendiran V, Devaraju N, Haddad M, Ravi N, Panigrahi L, Paul J Mol Ther. 2024; 32(3):663-677.

PMID: 38273654 PMC: 10928131. DOI: 10.1016/j.ymthe.2024.01.023.


Evaluation of Mono- and Bi-Functional GLOBE-Based Vectors for Therapy of β-Thalassemia by Gene Addition and Mutation-Specific RNA Interference.

Koniali L, Flouri C, Kostopoulou M, Papaioannou N, Papasavva P, Naiisseh B Cells. 2023; 12(24).

PMID: 38132168 PMC: 10741507. DOI: 10.3390/cells12242848.


References
1.
Frank F, Sonenberg N, Nagar B . Structural basis for 5'-nucleotide base-specific recognition of guide RNA by human AGO2. Nature. 2010; 465(7299):818-22. DOI: 10.1038/nature09039. View

2.
Amendola M, Passerini L, Pucci F, Gentner B, Bacchetta R, Naldini L . Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther. 2009; 17(6):1039-52. PMC: 2835189. DOI: 10.1038/mt.2009.48. View

3.
Weber K, Mock U, Petrowitz B, Bartsch U, Fehse B . Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene Ther. 2009; 17(4):511-20. DOI: 10.1038/gt.2009.149. View

4.
Ippolito G, Dekker J, Wang Y, Lee B, Shaffer 3rd A, Lin J . Dendritic cell fate is determined by BCL11A. Proc Natl Acad Sci U S A. 2014; 111(11):E998-1006. PMC: 3964079. DOI: 10.1073/pnas.1319228111. View

5.
Park J, Heo I, Tian Y, Simanshu D, Chang H, Jee D . Dicer recognizes the 5' end of RNA for efficient and accurate processing. Nature. 2011; 475(7355):201-5. PMC: 4693635. DOI: 10.1038/nature10198. View